Acumen Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Noncurrent
Acumen Pharmaceuticals, Inc. (ABOS) had Debt Securities, Available-for-sale, Noncurrent of $9.44 million as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-03-26
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $9.44M.
- 2025-06-30: Debt Securities, Available-for-sale, Noncurrent $22.80M.
- 2025-03-31: Debt Securities, Available-for-sale, Noncurrent $48.80M.
- 2024-12-31: Debt Securities, Available-for-sale, Noncurrent $59.97M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2025-09-30 | $9.44M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $22.80M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $48.80M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $59.97M 10-K · filed 2026-03-26 |
| 2024-09-30 | $58.55M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $20.91M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $44.11M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $62.55M 10-K · filed 2025-03-27 |
| 2023-09-30 | $67.27M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $27.31M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $43.42M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $15.84M 10-K · filed 2024-03-26 |
| 2021-12-31 | $31.62M 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |